DCOY

Decoy Therapeutics Inc. is a biotechnology company focused on developing antiviral therapies. It is pioneering Designable Multi-Antivirals (D-MAVs), engineered to target shared mechanisms across various viruses, allowing a single drug to address multiple viral threats. The company utilizes its proprietary peptide conjugate platform, IMP³ACT, which combines AI-enabled design with rapid synthesis and manufacturing to facilitate antiviral development. Decoy's lead programs concentrate on respiratory viruses, aiming to provide effective treatment options for immunocompromised patients and address significant health challenges related to viral infections.